<DOC>
	<DOCNO>NCT00684632</DOCNO>
	<brief_summary>This study design determine whether KW-2246 superior placebo inferior immediate-release morphine relief breakthrough pain cancer patient .</brief_summary>
	<brief_title>A Phase III Clinical Study KW-2246 Breakthrough Pain Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>At time obtain write informed consent Provide write informed consent participate study voluntary basis . Between age 20 80 year ( inclusive ) . Outpatients live caregiver family member , inpatient . Regularly receive one follow opioid analgesic : sustainedrelease oral morphine , sustainedrelease oral oxycodone , fentanyl transdermal patch . The daily dosage regular opioid analgesic regimen maintain constant baseline period end study determine investigator . Require rescue medication least 0.5 time ( least every two day ) three time per day average determine investigator . Performance Status ( ECOG ) 3 less time give write informed consent.Be able receive diary training ability properly complete diary determine investigator . Have life expectancy least three month determine investigator . Be able receive diary training ability properly complete diary determine investigator . At time randomization The `` regular opioid analgesic '' use time give write informed consent take fix dosage throughout baseline period . The `` immediaterelease morphine '' use time give write informed consent ( OpsoÂ® ( morphine hydrochloride hydrate ) oral solution , morphine hydrochloride ( powder ) , morphine hydrochloride tablet ) take fix dosage 5 , 10 , 15 , 20 mg/dose throughout baseline period . Have receive rescue medication least 0.5 time three time per day average baseline period . Have pain intensity least 3 cm rat visual analog scale ( VAS ) immediately two rescue dos immediaterelease morphine baseline period , mean decrease least 1.8 cm least onethird VASrated pain intensity 30 minute dose compare predose value . Have receive diary training able properly complete diary baseline period . At time obtain write informed consent Intolerable adverse reaction ( define Attachment 3 ) opioids . Serious respiratory dysfunction . Asthma . Serious bradyarrhythmia . Serious hepatic dysfunction . Serious renal dysfunction . Susceptibility respiratory depression due condition increase intracranial pressure , head injury brain tumor . Patients history clinically significant adverse reaction combination opioid analgesic follow drugs/substances , currently receive expect receive study : Central nervous system depressant ( phenothiazine , benzodiazepine barbiturate ) , inhalation anesthetic , monoamine oxidase inhibitor , tricyclic antidepressant , skeletal muscle relaxant , antihistamine , ritonavir , alcohol , itraconazole , amiodarone , clarithromycin , diltiazem , fluvoxamine . History convulsive seizure ( except single episode infantile febrile convulsion ) . History hypersensitivity fentanyl . Current past history drug dependence narcotic abuse . Pregnant lactate woman , possibly pregnant woman , woman plan become pregnant . Participation clinical trial within 28 day prior give write informed consent . Prior exposure KW2246 . Patients judge investigator/subinvestigator inappropriate study . At time randomization Have experience intolerable adverse reaction ( define Attachment 3 ) opioids baseline period . Have receive , baseline period , morphine , oxycodone fentanyl formulation `` regular opioid analgesic '' use time give write informed consent . Use codeine , dihydrocodeine , opium , pethidine , buprenorphine , pentazocine , tramadol , butorphanol , eptazocine within seven day prior randomization ( except codeine daily dosages 60 mg dihydrocodeine daily dosage 30 mg treatment cough ) . Interventions may affect pain intensity rating , surgery , radiation therapy nerve bThe daily dosage systemicallyacting adjuvant analgesic drug analgesic activity modify baseline period.lock , within seven day prior randomization . Use narcotic antagonist within seven day prior randomization . The daily dosage systemicallyacting adjuvant analgesic drug analgesic activity modify baseline period . The daily dosage locallyacting adjuvant analgesic drug analgesic activity use relief cancer pain modify baseline period . The daily dosage codeine ( 60 mg/day ) dihydrocodeine ( 30 mg/day ) use treatment cough modify baseline period . Have follow result recent laboratory test conduct within seven day prior randomization : AST &gt; 5 time upper limit normal study site ( ULN ) ; ALT &gt; 5 time ULN ; Serum creatinine &gt; 1.5 time ULN . Dry mouth affect sublingual administration ( i.e. , poor compliance sublingual administration train placebo ) . Subjects judge investigator/subinvestigator inappropriate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pain , cancer</keyword>
</DOC>